单倍体与同胞、无关或脐血造血细胞移植治疗急性淋巴细胞白血病的比较
该回顾性多变量分析比较了成人急性淋巴细胞白血病缓解期接受单倍体(PTCy)与同胞全合、8/8相合无关、7/8相合无关或脐血移植的结局。主要目标为比较总生存。单倍体移植与同胞全合移植相比生存无差异但慢性GVHD更低;与8/8无关供者相比非复发死亡和GVHD更高;与7/8无关供者相比生存更优;与脐血移植相比早期生存更优。
要点
- 单倍体PTCy移植与同胞全合移植生存无差异,且慢性GVHD更低。
- 单倍体PTCy移植较8/8相合无关供者移植非复发死亡和GVHD更低。
- 单倍体PTCy移植较7/8相合无关供者及脐血移植早期生存更优。
核心结论
- 使用PTCy的单倍体造血细胞移植与同胞全合及8/8相合无关供者移植相比生存无差异且GVHD更少,是成人ALL完全缓解期首选的替代供者移植选择。
研究设计与样本
- 回顾性多变量分析,比较成人急性淋巴细胞白血病缓解期接受不同供者类型造血细胞移植的结局。
- 主要目标为比较单倍体(PTCy)与同胞全合、8/8相合无关、7/8相合无关或脐血移植的总生存。
主要发现
- 与同胞全合移植相比,单倍体移植的总生存、无白血病生存、非复发死亡、复发和急性GVHD无差异,但同胞全合移植慢性GVHD更高。
临床怎么用
- 对于成人ALL完全缓解期需异基因移植者,单倍体PTCy移植可作为优先替代供者选择,因其生存与同胞全合及8/8无关供者相当且GVHD更少。
局限性
- 回顾性研究设计可能存在选择偏倚和混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P ≤ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P ≤ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.
引用
- Wieduwilt MJ, Metheny L, Zhang MJ, et al. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Adv. 2022. PMID: 34547770. doi:10.1182/bloodadvances.2021004916
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。